Aaron Waxman
Pulmonary Disease · Boston, MANPI 1669461810
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Merck accounts for 68.4% of it on its own, with 6 other manufacturers making up the rest. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $869.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$60K
- Insmed, Inc.$17K
- Bayer$6K
- United Therapeutics Corporation$2K
- Vertex$2K
- Actelion Pharmaceuticals US, Inc.$167
- plus $15 from 1 others
Across 152 payments — averaging $50,323 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$6.8M
- United Therapeutics Corporation$332K
- Medtronic$249K
- Sumitomo Pharma America, Inc.$177K
- Baxter Healthcare$44K
- Janssen Research & Development, LLC$19K
What the payments were for
- Consulting fees$42,37948%
- Speaking & faculty fees$24,07027%
- Travel & lodging$18,56621%
- Food & beverage$2,8073%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 45 | $60,029 |
| Insmed, Inc. | 13 | $17,394 |
| Bayer | 4 | $6,272 |
| United Therapeutics Corporation | 30 | $2,448 |
| Vertex | 1 | $1,500 |
| Actelion Pharmaceuticals US, Inc. | 7 | $167 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,824 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $28,376 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $14,741 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $14,028 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $9,948 |
| Tadalafil | 24 | $7,656 |
| Sildenafil Citrate | 13 | $2,524 |
| Torsemide | 42 | $1,719 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 18 | $1,144 |
| Pyridostigmine Bromide | 18 | $1,109 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $892 |
| Omeprazole | 15 | $407 |
| Spironolactone | 20 | $237 |
| Furosemide | 23 | $169 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Kelsey SackBoston$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.